Lowenstein Jensen + Capreomycin (10)* price on request
- Known as:
- Lowenstein Jensen + Capreomycin (10)* price request
- Catalog number:
- MB-34138
- Product Quantity:
- 50 tubes
- Category:
- -
- Supplier:
- Kisbio
- Gene target:
- Lowenstein Jensen + Capreomycin (10)* price request
Related genes to: Lowenstein Jensen + Capreomycin (10)* price on request
- Gene:
- AAK1 NIH gene
- Name:
- AP2 associated kinase 1
- Previous symbol:
- -
- Synonyms:
- KIAA1048, DKFZp686K16132
- Chromosome:
- 2p13.3
- Locus Type:
- gene with protein product
- Date approved:
- 2003-07-21
- Date modifiied:
- 2015-08-24
- Gene:
- AAMDC NIH gene
- Name:
- adipogenesis associated Mth938 domain containing
- Previous symbol:
- C11orf67
- Synonyms:
- PTD015, FLJ21035, CK067
- Chromosome:
- 11q14.1
- Locus Type:
- gene with protein product
- Date approved:
- 2006-03-27
- Date modifiied:
- 2016-06-21
- Gene:
- ABCB10P1 NIH gene
- Name:
- ABCB10 pseudogene 1
- Previous symbol:
- ABCB10P, ABCB10P2
- Synonyms:
- M-ABC2, MABC2
- Chromosome:
- 15q11.2
- Locus Type:
- pseudogene
- Date approved:
- 2001-07-13
- Date modifiied:
- 2018-05-23
- Gene:
- ABHD12 NIH gene
- Name:
- abhydrolase domain containing 12
- Previous symbol:
- C20orf22
- Synonyms:
- DKFZP434P106, dJ965G21.2, BEM46L2, ABHD12A
- Chromosome:
- 20p11.21
- Locus Type:
- gene with protein product
- Date approved:
- 2001-06-21
- Date modifiied:
- 2018-09-25
- Gene:
- ABHD17A NIH gene
- Name:
- abhydrolase domain containing 17A
- Previous symbol:
- C19orf27, FAM108A1
- Synonyms:
- MGC5244
- Chromosome:
- 19p13.3
- Locus Type:
- gene with protein product
- Date approved:
- 2004-03-17
- Date modifiied:
- 2019-01-28
Related products to: Lowenstein Jensen + Capreomycin (10)* price on request
110V-to-100V Voltage Transformer 5 A capacity. Net price (not negotiatable). Voltage transformer may be locally prepared, instead of purchasing from Atto.110V-to-100V Voltage Transformer 5 A capacity. Net price (not negotiatable). Voltage transformer may be locally prepared, instead of purchasing from Atto.2,4,5_Tri_chlorophenoxyacetic Acid *Price on request240V-to-100V Voltage Transformer 5 A capacity. Net price (not negotiatable). Voltage transformer may be locally prepared, instead of purchasing from Atto.240V-to-100V Voltage Transformer 5 A capacity. Net price (not negotiatable). Voltage transformer may be locally prepared, instead of purchasing from Atto.anti_CENP_A(fission yeast)antibody, rabbit antibody*price on requestanti_Cnd2(fission yeast)antibody, rabbit antibody*price on requestanti_Cut15(fission yeast)antibody, rabbit antibody*price on requestanti_Cut8(fission yeast)antibody, rabbit antibody*price on requestanti_Cut9(fission yeast)antibody, rabbit antibody*price on requestanti_Dis1(fission yeast)antibody, rabbit antibody*price on requestanti_Dis1(P_S551)(fission yeast)antibody, rabbit antibody*price on requestanti_Mis4(fission yeast)antibody, rabbit antibody*price on requestanti_Nda4(fission yeast)antibody, rabbit antibody*price on requestanti_NIPBL(human,hMis4)antibody, rabbit antibody*price on request Related articles to: Lowenstein Jensen + Capreomycin (10)* price on request
- In order to disentangle the effects of drugs from placebo responses, several approaches have been used, such as a placebo run-in phase in which only placebo nonresponders, or poor responders, are considered for further randomization to either placebo or active treatment. This study is aimed at investigating the variability of placebo nonresponders obtained through the classical placebo run-in paradigm (group RUN) and through mismatch conditioning (group MIS), as done in our previous study. To do this, we simulated a real clinical trial in the laboratory, in which the placebo responders of both groups were discarded and the remaining nonresponders of both groups RUN and MIS were randomized to either continuing on placebo (groups RUN-P and MIS-P, respectively) or receiving topical 0.5% lidocaine (groups RUN-L and MIS-L, respectively) applied to the skin. By measuring pain thresholds, we found that the placebo nonresponders selected on the first day of the experiment showed different responses on the following day in both group RUN and MIS. This led to no significant differences between placebo and lidocaine in both groups. Although this is an experimental laboratory situation far from the clinical trial setting, these findings show that placebo nonresponders are not necessarily constant over time, both when a placebo run-in protocol is used and when nonresponders are created in the laboratory. This questions the reliability of selecting placebo nonresponders as a methodological approach in clinical research. Therefore, we suggest reconsidering the validity and usefulness of placebo run-in protocols. PERSPECTIVE: Placebo nonresponders are sometime selected for further randomization to either placebo or active treatment. In this experimental study, which is a laboratory simulation of a clinical trial, we found that placebo nonresponders vary from day to day, thus questioning their validity as a methodological approach in clinical research. - Source: PubMed
Publication date: 2025/01/11
Benedetti FabrizioThoen WilmaShaibani AzizArduino Claudia - The COVID-19 pandemic involved business closures (e.g., gyms), social distancing policies, and prolonged stressful situations that may have impacted engagement in health behaviors. Our study assessed changes in cancer-related health behaviors during the pandemic, specifically physical activity, fruit/vegetable intake, smoking/tobacco use, and alcohol consumption. - Source: PubMed
Publication date: 2025/01/09
Greteman Breanna BCole AllisonCharlton Mary EShannon JackilenKepka DeannaPaskett Electra DBorrayo Evelinn AStudts Jamie LThompson Hayley SScarinci IsabelHinton Lynn CholletChrischilles Elizabeth AGarcia-Auguste Crystal JChristini KailaAker HeatherPlascak Jesse JHarper Felicity W KBaskin Monica LBae SejongPandya VishrutiKim Young-IlFaseru BabalolaBefort ChristieKuo HanluenDignan MarkCanedo JuanChampion VictoriaDrake Bettina FDavis Kia LFriedman Debra LElsaid Mohamed IMama Scherezade KCohn Wendy F - Increasing industrial pollution and certain hazardous agricultural practices have led to the discharge of heavy toxic metals into the environment. Among different bioremediation techniques, biomineralization is the synthesis of biomineral crystals extracellularly or intracellularly. Several bacteria, such as Bacillus cereus, Pseudomonas stutzeri, Bacillus subtilis, and Lactobacillus sphaericus have been found to induce heavy metal precipitation and mineralization for bioremediation. This article summarizes the different biomineralization mechanisms of bacterial-induced heavy metal biomineralization, mainly microbial-induced carbonate precipitation (MICP), microbial-induced phosphate precipitation (MIPP), and microbial-induced sulphide precipitation (MISP). Moreover, bacterial structures such as cell wall, biofilm, and extracellular polymeric substances (EPS) influence mineralization and control bacterial compartmentalization of heavy metal precipitation. Several genes control the efficiency of biomineralization in bacteria, such as ureA, ureB, ureC, phoA, dsrA, dsrB, dsrC, dsrD, dsrE, luxS, and ompR. This biomineralization mechanism provides new and broad prospects for its application in soil improvement, industrial applications, and wastewater treatments. In addition, bacterial genetic modification holds immense potential for advancing the biomineralization process to meet diverse environmental and industrial needs. - Source: PubMed
Publication date: 2025/01/02
Mallick SouradipPradhan TrisnehiDas Surajit - Conflict-affected regions face severe reproductive health challenges that disproportionately impact adolescent girls and young women (AGYW) and children, who are especially vulnerable due to the breakdown of healthcare systems and limited access to essential services. AGYW are at heightened risk due to restricted access to family planning, prenatal care, and emergency obstetric services, while children face malnutrition, disease outbreaks, and developmental delays. These challenges have profound long-term consequences for both their physical and psychological well-being. This commentary explores the underlying causes of reproductive health challenges in conflict zones, including the collapse of healthcare infrastructure, increased sexual violence, forced displacement, and the specific vulnerabilities AGYW and children face. The commentary underscores the urgent need for interventions that address both immediate and systemic gaps in reproductive healthcare, particularly for AGYW and children. A unique policy framework is proposed, integrating emergency reproductive health interventions-such as mobile clinics and emergency health kits-with long-term strategies for rebuilding healthcare systems. The framework emphasizes gender-sensitive, context-specific approaches and sustained investments in healthcare infrastructure to effectively address these challenges and mitigate the long-term effects on vulnerable populations. By aligning with global and regional policy frameworks, including the Inter-Agency Working Group on Reproductive Health in Crises (IAWG) and the Minimum Initial Service Package (MISP), the commentary advocates for embedding reproductive health into all phases of humanitarian action-from emergency response to recovery. This integrated approach provides actionable recommendations to improve the well-being of AGYW, children, and other vulnerable populations, fostering sustainable advancements in reproductive health outcomes. - Source: PubMed
Publication date: 2024/12/27
Okeke Sylvester ReubenOkeke-Obayemi Deborah OluwatosinNjoroge Monicah RuguruYaya Sanni - Systemic lupus erythematosus (SLE) is a severe autoimmune/inflammatory disease. Patients with juvenile disease-onset and those of non-European ancestry are most severely affected. While the exact pathophysiology remains unknown, common and rare gene variants in the context of environmental exposure and epigenetic alterations are involved. This manuscript summarizes the current understanding of genetic and epigenetic contributors to SLE risk, manifestations and outcomes. - Source: PubMed
Publication date: 2024/12/11
Charras AmandineHiraki Linda TLewandowski LauraHedrich Christian M